| Nancy Venditti, MD | |
|
195 Worcester St, Suite 102, Wellesley, MA 02481-5568 | |
| (617) 219-1510 | |
| (617) 219-1512 |
| Full Name | Nancy Venditti |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 37 Years |
| Location | 195 Worcester St, Wellesley, Massachusetts |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376596163 | NPI | - | NPPES |
| 073231 | Other | MA | TUFTS |
| 0015266 | Other | MA | NEIGHBORHOOD HEALTH |
| 3096262 | Medicaid | MA | |
| J12782 | Other | MA | BLUE CROSS |
| V293 | Other | MA | HARVARD PILGRIM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 73231 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Brigham And Women's Hospital | Boston, MA | Hospital |
| Emerson Hospital - | W concord, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emerson Practice Associates, Inc | 8123188117 | 192 |
| Afc Physicians Of Massachusetts, Pc | 9234321308 | 29 |
| Mass General Brigham Urgent Care Llc | 9436470119 | 82 |
News Archive
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
In this brief, researchers analyze the cost burden associated with excess rates of diseases such as diabetes, hypertension, stroke and renal disease among Hispanics and African Americans relative to non-Hispanic whites. The study predicts that in 2009, "Medicare alone will spend an extra $15.6 billion while private insurers will incur $5.1 billion in additional costs due to elevated rates of chronic illness among African Americans and Hispanics."
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP, one of the largest water and sewage services providers in the world based on the number of customers, announces today its results for the second quarter 2010.
A scientific panel of the European Food Safety Authority (EFSA) published its positive opinion on a disease risk reduction health claim dossier for oat beta-glucan on 8. December 2010, following an application from CreaNutrition AG submitted pursuant to Article 14 of the EC regulation on nutrition and health claims.
› Verified 3 days ago
| Entity Name | Emerson Practice Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508020199 PECOS PAC ID: 8123188117 Enrollment ID: O20081120000518 |
News Archive
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
In this brief, researchers analyze the cost burden associated with excess rates of diseases such as diabetes, hypertension, stroke and renal disease among Hispanics and African Americans relative to non-Hispanic whites. The study predicts that in 2009, "Medicare alone will spend an extra $15.6 billion while private insurers will incur $5.1 billion in additional costs due to elevated rates of chronic illness among African Americans and Hispanics."
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP, one of the largest water and sewage services providers in the world based on the number of customers, announces today its results for the second quarter 2010.
A scientific panel of the European Food Safety Authority (EFSA) published its positive opinion on a disease risk reduction health claim dossier for oat beta-glucan on 8. December 2010, following an application from CreaNutrition AG submitted pursuant to Article 14 of the EC regulation on nutrition and health claims.
› Verified 3 days ago
| Entity Name | Afc Physicians Of Massachusetts, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902123276 PECOS PAC ID: 9234321308 Enrollment ID: O20101007000509 |
News Archive
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
In this brief, researchers analyze the cost burden associated with excess rates of diseases such as diabetes, hypertension, stroke and renal disease among Hispanics and African Americans relative to non-Hispanic whites. The study predicts that in 2009, "Medicare alone will spend an extra $15.6 billion while private insurers will incur $5.1 billion in additional costs due to elevated rates of chronic illness among African Americans and Hispanics."
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP, one of the largest water and sewage services providers in the world based on the number of customers, announces today its results for the second quarter 2010.
A scientific panel of the European Food Safety Authority (EFSA) published its positive opinion on a disease risk reduction health claim dossier for oat beta-glucan on 8. December 2010, following an application from CreaNutrition AG submitted pursuant to Article 14 of the EC regulation on nutrition and health claims.
› Verified 3 days ago
| Entity Name | Drx Natick Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114293917 PECOS PAC ID: 3072761428 Enrollment ID: O20120911000040 |
News Archive
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
In this brief, researchers analyze the cost burden associated with excess rates of diseases such as diabetes, hypertension, stroke and renal disease among Hispanics and African Americans relative to non-Hispanic whites. The study predicts that in 2009, "Medicare alone will spend an extra $15.6 billion while private insurers will incur $5.1 billion in additional costs due to elevated rates of chronic illness among African Americans and Hispanics."
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP, one of the largest water and sewage services providers in the world based on the number of customers, announces today its results for the second quarter 2010.
A scientific panel of the European Food Safety Authority (EFSA) published its positive opinion on a disease risk reduction health claim dossier for oat beta-glucan on 8. December 2010, following an application from CreaNutrition AG submitted pursuant to Article 14 of the EC regulation on nutrition and health claims.
› Verified 3 days ago
| Entity Name | Mass General Brigham Urgent Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720486830 PECOS PAC ID: 9436470119 Enrollment ID: O20150605002309 |
News Archive
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
In this brief, researchers analyze the cost burden associated with excess rates of diseases such as diabetes, hypertension, stroke and renal disease among Hispanics and African Americans relative to non-Hispanic whites. The study predicts that in 2009, "Medicare alone will spend an extra $15.6 billion while private insurers will incur $5.1 billion in additional costs due to elevated rates of chronic illness among African Americans and Hispanics."
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP, one of the largest water and sewage services providers in the world based on the number of customers, announces today its results for the second quarter 2010.
A scientific panel of the European Food Safety Authority (EFSA) published its positive opinion on a disease risk reduction health claim dossier for oat beta-glucan on 8. December 2010, following an application from CreaNutrition AG submitted pursuant to Article 14 of the EC regulation on nutrition and health claims.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nancy Venditti, MD 195 Worcester Street, Suite 102, Wellesley, MA 02481 Ph: (617) 219-1510 | Nancy Venditti, MD 195 Worcester St, Suite 102, Wellesley, MA 02481-5568 Ph: (617) 219-1510 |
News Archive
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
In this brief, researchers analyze the cost burden associated with excess rates of diseases such as diabetes, hypertension, stroke and renal disease among Hispanics and African Americans relative to non-Hispanic whites. The study predicts that in 2009, "Medicare alone will spend an extra $15.6 billion while private insurers will incur $5.1 billion in additional costs due to elevated rates of chronic illness among African Americans and Hispanics."
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP, one of the largest water and sewage services providers in the world based on the number of customers, announces today its results for the second quarter 2010.
A scientific panel of the European Food Safety Authority (EFSA) published its positive opinion on a disease risk reduction health claim dossier for oat beta-glucan on 8. December 2010, following an application from CreaNutrition AG submitted pursuant to Article 14 of the EC regulation on nutrition and health claims.
› Verified 3 days ago
Deborah Hadley, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 195 Worcester St, Suite 102, Wellesley, MA 02481 Phone: 617-219-1510 Fax: 617-219-1512 | |
Dr. Burt Whitney Hall, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 65 Walnut St, Suite 590, Wellesley, MA 02481 Phone: 781-237-3395 Fax: 781-237-3397 | |
Ida P Gorenburg, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 230 Worcester St, Internal Medicine, Wellesley, MA 02481 Phone: 781-431-5220 Fax: 781-431-5526 | |
James S Sidel, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 4 Falmouth Rd, Wellesley, MA 02481 Phone: 781-237-3057 | |
David John Wenzel, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: Marino Center For Progressive Health, 372 Washington Street, Wellesley, MA 02481 Phone: 781-235-5200 Fax: 781-235-1103 | |
Dr. Jessica Suzanne Mosher, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 20 William St Ste G15, Wellesley, MA 02481 Phone: 781-591-4234 Fax: 781-369-9737 | |
Charles C Pao, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 40 Walnut Street, Suite 102, Wellesley, MA 02481 Phone: 781-943-3000 Fax: 781-943-3037 |